How is low molecular weight heparin (LMWH) monitored during the treatment of hereditary and acquired hypercoagulability?

Updated: Jan 05, 2018
  • Author: Paul Schick, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

In general, LMWHs are administered without routine laboratory monitoring because the dosage effects are fairly consistent. The most common method for monitoring LMWH is a chromogenic assay for anti–factor Xa activity. This assay does not accurately estimate risk for bleeding or whether anticoagulation is sufficient to prevent thrombosis.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!